Given that pDCs are known to be one of the major sources of type I IFNs (TI-IFNs) (46), and cytotoxic therapies such as chemotherapy and radiation therapy are known to cause large amounts of TI-IFN release (47, 48), we wanted to explore the contribution of pDCs and TI-IFNs in our observed tumor control following treatment with Alb-Flt3L plus cisplatin. The gene discussed is IFNA1; the disease is neoplasm.